European Basic Pharmaceutical Products Gross Value Added Per Employee FTE by Country

In 2023, Switzerland stands out as the leader in Gross Value Added (GVA) per employee Full-Time Equivalent (FTE) among European countries in the basic pharmaceutical products sector, valued at 1.13 million Euros. The Netherlands and Belgium follow at 0.3135 and 0.2158 million Euros, respectively. Countries such as Germany, Portugal, and Eastern European nations like Romania and Hungary show significantly lower values, with Romania recording the lowest at 0.0319 million Euros per employee FTE. This indicates a wide disparity in productivity or economic output per employee among these European nations.

Looking ahead, it is crucial to monitor the impact of technological advancements and potential regulatory shifts on the productivity of the workforce in the pharmaceutical sector across different countries. The increasing emphasis on digital transformation and biotechnology innovation may enhance the GVA per employee, especially in innovation-driven economies like Switzerland and the Netherlands. Conversely, countries with lower current GVA may either benefit from technology adoption or face challenges if unable to capitalize on these advancements.